Pfizer Canada ULC and BioNTech SE announced that Health Canada has expanded the Interim Order authorization for their COVID-19 vaccine to include individuals 12 to 15 years of… read more.
Department of Health & Social Care (UK) Statement made on 7 May 2021:There have been reports of extremely rare adverse events of concurrent thrombosis (blood clots) and thrombocytopenia… read more.
A single dose of either the Pfizer/BioNTech or the AstraZeneca/Oxford COVID-19 vaccines reduced household transmission by up to a half, according to new research by Public Health England… read more.
Johnson & Johnson announced publication in the New England Journal of Medicine of primary data from the Phase III ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed… read more.
Johnson & Johnson announced that vaccinations with JNJ 78436735, the Company’s COVID-19 single-shot vaccine, will resume for all adults aged 18 years and older in the U.S., under… read more.
Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted… read more.
Johnson & Johnson Statement on COVID-19 Vaccine (Updated) :The safety and well-being of the people who use our products is a number one priority. We are aware of… read more.
A hypothesis has been put forward as to why COVID-19 Vaccine AstraZeneca (ChAdOx1 nCov-19) seems to trigger an abnormal and potentially life-threatening combination of blood clotting and low… read more.
The AstraZeneca US Phase III trial of AZD 1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and… read more.
Pfizer Inc. and BioNTech SE announced that, in a Phase III trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection,… read more.
Celltrion Group announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for the company’s anti-COVID-19 monoclonal antibody… read more.
Positive high-level results from the primary analysis of the Phase III trial of AZD 1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
